
Model-Informed Drug Development

2021 Virtual Conference

Introduction to FIH/Phase 1 Track
Kevin Dykstra, PhD FCP
Vice President, Consulting Services



Drug Development Phases



Application of Modeling & Simulation in Phase 1

Questions to be Addressed

First in Human Studies

- How much can we give safely?
- What is the human exposure?
- Does the drug engage with its target?

Later ...

- What affects exposure?
 - Other drugs? Food? Physiological impairment?
- How do we administer the drug?
 - Exposure with new formulations
 - Bridging among study populations




Image from Badea & Johnson. Analytical Cellular Pathology, 35(4):205-227 (2011).



Image from True Phantom Solutions



Phase 1 Speakers



Monika Twarogowska, PhD Applications Manager Simulations Plus, Inc.

Using a population PK/PD model developed on Phase I to select the dose for Phase II: an example with an IgG1 mAb



Yogesh Patel, PhD
Associate Director, Quantitative Clinical Pharmacology
Simulations Plus, Inc.
Pharmacometrics in Phase 1: First in Human and Dose Selection for Phase 2



Michael Bolger, PhD
Founding Scientist, Research & Development
Simulations Plus, Inc.
GastroPlus® DDI Standards Update



Phase 1 Poster Presenters



KyungHee Yang, PhD
Senior Scientist
Simulations Plus, Inc.
Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Elevations Using DILIsym Quantitative Systems Toxicology Modeling



Vinal Lakhani

Scientist 1
Simulations Plus, Inc.
Quantitative Systems Toxicology Identifies the Mechanism and Data Gaps for Evaluating the Hepatotoxicity of Compound V



Bill van Osdol, PhD
Principal Application Specialist
Simulations Plus, Inc.
Computational Simulation of Dermal Absorption from Complex Topical Formulations





Model-Informed Drug Development

2021 Virtual Conference



Learn More! www.simulations-plus.com



